Your session is about to expire
← Back to Search
Bintrafusp alfa for Tumors
Study Summary
This trial is testing a new cancer drug for people with urothelial cancer that has progressed after other treatments.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 146 Patients • NCT04246489Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any North American locations conducting this clinical investigation?
"At present, this clinical trial is operating in 6 different locations, such as Toronto, Cincinnati and Seattle. It would be best for participants to choose the closest medical centre to reduce travel requirements."
What is the main aim of this research?
"According to the information released by Merck KGaA, Darmstadt, Germany, this clinical trial's primary objective will be measured over three years and is defined as Confirmed overall response rate (ORR) - Investigator assessment. Additionally, secondary outcomes being evaluated include Number of participants with positive anti-drug antibodies (ADAs), Percentage of participants with positive ADAs against bintrafusp alfa, and Concentration observed immediately before next dosing for bintrafusp alfa."
Is this medical experiment the initial of its kind?
"Since its inception in 2016, the research into Bintrafusp alfa has been sponsored by Merck Sharp & Dohme LLC. This led to a phase 1 drug approval for 829 patients and currently there are active investigations of this medication occurring in 21 different countries with 59 cities participating."
What other scientific investigations have focused on Bintrafusp alfa?
"Currently, 22 studies exploring Bintrafusp alfa are live with 2 of them in Phase 3. Though the bulk of these clinical trials occur in Henderson, Nevada, there exist a total of 285 locations conducting research on this drug."
Has the FDA officially sanctioned Bintrafusp alfa?
"The safety of Bintrafusp alfa is calculated to be a 1 on our company's rating system, as this clinical trial is in its early stages and has very limited data on the efficacy and safety."
How many patients have been enlisted for this research endeavor?
"This experiment is no longer accepting applicants as the last modification to its listing was made on September 22nd 2022. Nevertheless, there are several other clinical trials still open for patients with cancer (2380) and Bintrafusp alfa (22)."
Are there any open slots available for this research project?
"The clinical trial registry on clinicialtrials.gov suggests that this particular study, which was first announced on October 15th 2020 and last updated September 22nd 2022, is not presently searching for participants. Nevertheless, 2401 other studies are actively recruiting now."
Share this study with friends
Copy Link
Messenger